ABOUT YolTech

YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing.

37M
+

USD Raised
80
+

Patents Filed
4
+

Programs in Clinical Development

DEVELOPMENT

2025
- Apr
  
  FDA ODD designation for YOLT-202
- Jun
  
  FDA IND clearance for YOLT-101
2024
- Feb
  
  Patent granted for base editor
- Mar
  
  NMPA IND Clearance for YOLT-201
- Apr
  
  Patent granted for CRISPR/Cas
- Apr
  
  First human POC for YOLT-101
- Aug
  
  First human POC for YOLT-203
- Sep
  
  FDA RPDD and ODD designation for YOLT-203
2023
- Mar
  
  GMP manufacturing facility established in Nanjing
- Dec
  
  First human POC for YOLT-201
2021
- Jul
  
  YolTech founded in Shanghai

2025
2024
2023
2021